2023 Fiscal Year Final Research Report
Development of a Total Net Cholesterol Efflux Capacity Analysis Method for Clinical Laboratory Applications
| Project/Area Number |
21K15641
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52010:General internal medicine-related
|
|---|
| Research Institution | Teikyo University (2023)
Tokyo Medical and Dental University (2021-2022) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 高比重リポタンパク / 粥状動脈硬化 / コレステロール引き抜き能 / リン脂質引き抜き能 |
|---|
| Outline of Final Research Achievements |
High-density lipoprotein (HDL) has cholesterol efflux capacity (CEC) to prevent atherosclerosis. We developed a highly accurate, simple, and safe method for CEC assessment using liposomes and BODIPY-labelled cholesterol instead of cultured cells or radioactive materials, which we named the immobilized liposome-linked gel bead (ILG) method. The ILG method can be performed in clinical practice. However, our previous study showed that bilirubin causes a positive error in the CEC value. Therefore, in this study, we attempted to improve the effect of bilirubin levels on the ILG method.It was found that bilirubin emitted fluorescence in the measurement setup of the ILG method.The positive error due to bilirubin could be improved by approximately 70% by shifting the excitation wavelength. Furthermore, the use of bilirubin oxidase improved the false high value of CEC by approximately 80%.
|
| Free Research Field |
臨床検査医学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究により、肝機能障害や新生児黄疸などの高ビリルビン血症検体のCEC値が測定できるようになった。特にILG法はCVDリスクを早期に評価するスクリーニング検査としての臨床導入を視野に入れているため、高ビリルビンの黄疸血清などの様々な検体への適用性を担保することが重要である。今回のビリルビンによる陽性誤差の改善は、ビリルビンが正常範囲にある患者にとっても有意義である。本研究で得られた結果は、BODIPY標識コレステロールを用いたCEC測定法全般において、ビリルビンが関与する測定値への影響の解決に大きく貢献すると考えられる。
|
